| 33.22 Data as of May 17 |  +1.27 / +3.97%Today’s Change | 17.96 Today|||52-Week Range 42.67 | -2.98% Year-to-Date |
| Previous close | 31.95 |
| Today’s open | 32.19 |
| Day’s range | 31.89 - 33.50 |
| Volume | 48,296 |
| Average volume (3 months) | 32,651 |
| Market cap | $558.3M |
| Dividend yield | -- |
| Earnings growth (last year) | -809.09% |
| Earnings growth (this year) | +74.02% |
| Earnings growth (next 5 years) | +22.00% |
| Revenue growth (last year) | +35.51% |
| P/E ratio | NM |
| Price/Sales | 87.95 |
| Price/Book | 8.33 |
| Today’s change | Today’s % change | |
|---|---|---|
| LGNDLigand Pharmaceutica... | +1.32 | +4.95% |
| OREXOrexigen Therapeutic... | -0.01 | -0.17% |
| CCXIChemoCentryx Inc | -0.16 | -1.16% |
| MACKMerrimack Pharmaceut... | +0.04 | +0.73% |
| Next reporting date | May 29, 2013 |
| EPS forecast (this quarter) | -$0.41 |
| Annual revenue (last year) | $2.4M |
| Annual profit (last year) | -$43.6M |
| Net profit margin | -1,784.19% |
Sector Health Technology |
Industry Pharmaceuticals: Other |
President, Chief Executive Officer & Director Mark E. Pruzanski, MD |
Chief Financial Officer, Secretary & Treasurer Barbara Gayle Duncan, MBA, CPA |
Corporate headquarters New York, New York |
.
